Adaptimmune Therapeutics (ADAP)
0.29
0.01 (3.57%)
At close: Mar 21, 2025, 3:59 PM
0.30
3.90%
After-hours: Mar 21, 2025, 06:58 PM EDT
3.57% (1D)
| Bid | 0.3 |
| Market Cap | 12.16M |
| Revenue (ttm) | 4.86M |
| Net Income (ttm) | -1.25M |
| EPS (ttm) | -0.17 |
| PE Ratio (ttm) | -1.68 |
| Forward PE | -1.24 |
| Analyst | Buy |
| Ask | 0.31 |
| Volume | 4,904,938 |
| Avg. Volume (20D) | 1,543,525 |
| Open | 0.31 |
| Previous Close | 0.28 |
| Day's Range | 0.28 - 0.31 |
| 52-Week Range | 0.26 - 1.65 |
| Beta | 2.51 |
About ADAP
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa...
Industry Biotechnology
Sector Healthcare
IPO Date May 6, 2015
Employees 449
Stock Exchange NASDAQ
Ticker Symbol ADAP
Website https://www.adaptimmune.com
Analyst Forecast
According to 5 analyst ratings, the average rating for ADAP stock is "Buy." The 12-month stock price forecast is $1.5, which is an increase of 425.95% from the latest price.
Stock ForecastsNext Earnings Release
Adaptimmune Therapeutics is scheduled to release its earnings on May 14, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 days ago
-37.65%
Adaptimmune Therapeutics shares are trading lower ...
Unlock content with
Pro Subscription
4 months ago
-23.28%
Adaptimmune Therapeutics shares are trading lower. The company reported Q3 financial results.
